04/05/2022 - Adaptive Biotechnologies Corporation: Adaptive Biotechnologies Q1 2022 Earnings Presentation

Safe Harbor

This presentation has been prepared by Adaptive Biotechnologies Corporation ("we," "us," "our," "Adaptive" or the "Company") and is made for informational purposes only. The information set forth herein does not purport to be complete or to contain all relevant information. Statements contained herein are made as of the date of this presentation unless stated otherwise. This presentation shall not constitute an offer to sell or the solicitation of an offer to buy securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction.

This presentation contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are intended to be covered by the "safe harbor" created by those sections. Forward-looking statements are neither historical facts nor

assurances of future performance. Instead, they are based on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, our development plans, our preclinical and clinical results and other future conditions. In some cases, you can identify forward-looking statements by the following words: "may," "will," "could," "would," "should," "expect," "intend," "plan," "anticipate," "believe," "estimate," "predict," "project," "potential," "continue," "ongoing" or the negative of these terms or

other comparable terminology, although not all forward-looking statements contain these words. All statements, other than statements of historical facts, contained in this presentation are forward looking statements, including statements regarding the ability to map adaptive immune responses to target disease states, the ability to leverage any such findings to advance solutions to diagnose, treat and prevent infectious diseases; regarding our future financial or business performance, conditions, plans, prospects, trends or strategies and other financial and business matters; our current and prospective products and product candidates; FDA clearance or authorization of any products; planned non-IDE clinical studies, clinical trials and preclinical activities, research and development costs, current and prospective collaborations; the estimated size of the market for our products and product candidates; the timing and success of our development and commercialization of current products and product candidates; the availability of alternative therapies for our target markets; and the other risks and uncertainties described in our filings with the Securities and Exchange Commission including the Risk Factors and Management's Discussion and Analysis of Financial Condition and Results of Operations sections of our most recently filed Quarterly Reports on Form 10-Q and our Annual Report on Form 10-K, including our most recent Annual Report on Form 10-K filed on February 15, 2022. Although we believe the expectations reflected in such forward-looking statements are reasonable, we can give no assurance that such expectations will prove to be correct. Risks and uncertainties could cause actual results to differ materially from those expressed in our forward-looking statements. Accordingly, readers are cautioned not to place undue reliance on these forward-looking statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein.

Certain information contained in this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and the Company's own internal estimates and research. While the Company believes these third-party sources to be reliable as of the date of this presentation, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, all of the market data included in this presentation involves a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. Finally, while we believe our own internal research is reliable, such research has not been verified by any independent source.

Business areas of focus: MRD and Immune Medicine

Executed strategic and workforce reorganization around two key Business Areas

Clinical diagnostics, drug discovery and research informed by our TCR-Antigen Map.

Q1 2022 Key Highlights

MRD Business

• ◼ Significant clonoSEQ test volume growth of 45% vs prior year

• ◼ Sales force hiring and training completed

• ◼ NCCN updated ALL guideline includes NGS MRD at additional timepoints

• ◼ Signed expanded pan-portfolio agreement in MM and CLL with pharma partner

• ◼ Recognized $3M in milestone revenue from pharma partner

• ◼ Pharma partnerships using immunoSEQ/T-MAP across infectious disease, oncology and autoimmune increasing (+100% pharma rev growth vs prior year)

• ◼ Clinical validation data supports T-Detect Lyme offering in 2022

• ◼ T-Detect clinical validation protocol for IBD finalized; study to initiate in 2022

• ◼ Genentech partnership on track with both shared and private products

MRD Business: clonoSEQ clinical testing

Growth experienced across the board…

• ◼ Q1'22 test delivered volume +45% vs P/Y; +12% vs P/Q

  • ❑ ~320 ordering accounts in Q1 (+36% vs P/Y)

  • ❑ ~1,200 ordering HCPs in Q1 (+53% vs P/Y)

  • ❑ Unique patients tested increased (59% vs P/Y)

• ◼ ~30% of MRD tests delivered by blood

clonoSEQ test volume

7,698

Q1'21

Q2'21

Q3'21

Q4'21

Q1'22

ASP ~$800

~$950-$1000

clonoSEQ test volume under new reporting to include tech transfer volume from international sites

Strategy to cement leadership in lymphoid cancers…

Three priority areas for investment

• ◼ HCP education & adoption: field force expansion & training

• ◼ Product development: expanding into NHL using cfDNA

• ◼ Customer experience: integrating into customer ordering systems

Market expansion in community

Penetrate deeper in institutional accounts

Multiple Myeloma in blood

400K patients

Expand into

NHL

This is an excerpt of the original content. To continue reading it, access the original document here.